UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q1 2023 Financial Results May 9, 2023 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as ...

Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head-Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Terry Coyne – Executive Vice President and Chief Financial Officer Chris Hite – Executive Vice President and Vice Chairman Conference Call Participants Chris Shibutani – Goldman Sachs Chris Sch ...

公司专利收购与财务表现 - 公司是生物制药专利权最大的买家，也是生物制药行业创新的领先资助者[68] - 公司自1996年成立以来，在专利市场上一直是先驱，拥有超过35种商业产品的专利，包括Vertex的Trikafta、Kalydeco、Orkambi和Symdeko、Biogen的Tysabri、AbbVie和强生的Imbruvica、爱尔康和辉瑞的Xtandi、GSK的Trelegy、诺华的Promacta、辉瑞的Nurtec ODT、强生的Tremfya、罗氏的Evrysdi、吉利德的Trodelvy以及11种开发阶段的产品候选[69] - 公司通过多种结构方式收购产品专利，包括第三方专利、合成专利、上市和发展资本以及并购相关的专利[73][74][75][76] - 公司的财务报告主要将收购的专利视为现金流投资，根据预期现金流量计算有效利率，通过逐步确认收益的方式将其纳入收入中[79] 财务表现与非GAAP指标 - 公司的主要非GAAP指标包括调整后的现金收入、调整后的EBITDA和调整后的现金流，用于评估公司的现金流能力和业绩[81] - 第一季度2023年，经营活动提供的净现金为10亿美元，较2022年的4.603亿美元有所增长[86] - 第一季度2023年，调整后的现金收入为11亿美元，较2022年的6.046亿美元有所增长[87] - 第一季度2023年，调整后的EBITDA为10亿美元，较2022年的5.557亿美元有所增长[88] - 第一季度2023年，调整后的现金流为9.734亿美元，较2022年的3.671亿美元有所增长[89] 版税收入与资产收购 - 公司的投资组合包括超过35种上市疗法和11种开发阶段的产品候选，主要涉及罕见疾病、癌症、神经病学、传染病、血液学和糖尿病等治疗领域[83] - 公司的金融版税资产代表对现金流流的投资，我们使用有效利率法计算利息收入[93] - 公司的无形版税资产收入来自Januvia、Janumet和其他DPP-IV产品的销售[94] - 公司在2023年第一季度投资了6.18亿美元用于版税、里程碑和相关资产[134] 现金流与投资活动 - 公司主要的流动性来源是运营活动提供的现金，2023年第一季度和2022年分别产生了10亿美元和4.603亿美元的净现金流[142] - 公司在2023年第一季度的经营活动现金流提供额增加了5.736亿美元，主要是由于来自金融版税资产的现金收款增加了5.299亿美元，包括与Zavzpret相关的4.75亿美元里程碑付款[144] - 公司在2023年第一季度的投资活动中使用了5.585亿美元，主要用于收购金融版税资产，以及市场证券的净现金提供减少了7.29万美元[144] 股息支付与股份回购 - 公司在2023年第一季度向持有人支付了8.86亿美元和2022年第一季度支付了8.23亿美元的股息[151] - 公司在2023年3月董事会授权了一项股份回购计划，最多可回购10亿美元的普通A类股份[151]

Royalty Pharma plc (NASDAQ:RPRX) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head of Investor Relations & Communications Pablo Legorreta - Founder & Chief Executive Officer Christopher Hite - Executive Vice President & Vice Chairman Marshall Urist - Executive Vice President & Head of Research and Investments Terry Coyne - Executive Vice President & Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sach ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (St ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q3 2022 Financial Results November 8, 2022 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are mad ...

Royalty Pharma plc (NASDAQ:RPRX) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants George Grofik - SVP, Head, IR & Communications Pablo Legorreta - Founder and Chief Executive Officer Marshall Urist - Executive Vice President and Head of Research and Investments Terry Coyne – Executive Vice President and Chief Financial Officer Christopher Hite - Executive Vice President and Vice Chairman Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Chris ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants George Grofik - SVP, Head, IR & Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP & Head, Research & Investments Terry Coyne – EVP & CFO Chris Hite - Vice Chairman Conference Call Participants Chris Shibutani - Goldman Sachs Chris Schott - J.P. Morgan Terence Flynn - Morgan Stanley Andrew Baum - Citi Steven Scala - Cowen Geoff Meacham - Bank of America Mike DiFiore - Evercore As ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q2 2022 Financial Results August 4, 2022 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made ...